Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022

Rhea-AI Summary

Achieve Life Sciences (Nasdaq: ACHV) will report its first quarter financial results and provide an update on its cytisinicline development program on May 12, 2022, at 4:30 PM EDT. Cytisinicline aims to assist in smoking cessation by targeting nicotine receptors in the brain, yet remains an investigational product and is not FDA-approved in the U.S. Tobacco usage leads to over eight million deaths globally each year, highlighting the importance of Achieve's mission. More details can be accessed through their webcast.

SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its first quarter financial results and provide an update on the cytisinicline development program on Thursday, May 12, 2022, at 4:30 PM EDT.

To access the webcast, please use the following link 1Q22 Earnings Webcast. Alternatively, you may access the live conference call by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 3887417. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.^1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.² Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve, visit www.achievelifesciences.com.

Investor Relations Contact
Rich Cockrell
achv@cg.capital
(404) 736-3838

Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485

References 
¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
² U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.

FAQ

When will Achieve Life Sciences report its Q1 financial results?

Achieve Life Sciences will report its first quarter financial results on May 12, 2022, at 4:30 PM EDT.

What is cytisinicline developed by Achieve Life Sciences?

Cytisinicline is a plant-based alkaloid aimed at aiding smoking cessation by interacting with nicotine receptors in the brain.

Is cytisinicline approved by the FDA?

No, cytisinicline is an investigational product candidate and has not been approved by the FDA for any indication in the United States.

How can I access Achieve Life Sciences' earnings webcast?

The earnings webcast can be accessed through the link provided in the press release or by dialing the provided conference call numbers.